8-K current report · filed Nov 5, 2026

Pacira BioSciences, Inc. (PCRX) 8-K Current Report: November 5, 2026

Item 7.01PCRX overview

Short answer

Pacira BioSciences, Inc. (PCRX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure). Viatris’ tender offer values Pacira at $36.50 per share in cash, subject to withholding taxes and transaction conditions.

Pacira BioSciences, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Viatris’ tender offer values Pacira at $36.50 per share in cash, subject to withholding taxes and transaction conditions
  • Pacira expected to become Viatris’ wholly owned subsidiary following the merger
  • No September 30, 2026 quarterly earnings release or conference call during the proposed transaction
  • Pacira withdrew previously issued 2026 financial guidance, removing near-term operating visibility
  • Investor focus shifts to offer completion, regulatory approvals and minimum tender condition risk

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Pacira BioSciences, Inc. 8-K filings

Get the next PCRX 8-K as it lands

Follow PCRX for push alerts, or ask the research agent what this filing means.